The tumor immune microenvironment is a determinant of response to cancer
immunotherapy and, in many cases, is prognostic for patient survival independently of the …

Lung cancer accounts for the main proportion of malignancy-related deaths and most
patients are diagnosed at an advanced stage. Immunotherapy and targeted therapy have …

Radiotherapy (RT) is still one of the standard cancer therapies, with up to two third of all
cancer patients with solid tumors being irradiated in the course of their disease. The aim of …

Objective Metabolic biomarkers are expected to decode the phenotype of gastric cancer
(GC) and lead to high-performance blood tests towards GC diagnosis and prognosis. We …

Artificial intelligence (AI) indicates the application of machines to imitate intelligent behaviors
for solving complex tasks with minimal human intervention, including machine learning and …

Immune checkpoint inhibitors (ICIs) have dramatically enhanced the treatment outcomes for
diverse malignancies. Yet, only 15–60% of patients respond significantly. Therefore …

Purpose The first aim of the trial is to study feasibility of combined programmed death protein
ligand 1/cytotoxic T-lymphocyte-associated protein 4 inhibition concomitant to radiotherapy …

Strong rationale and a growing number of preclinical and clinical studies support combining
radiotherapy and immunotherapy to improve patient outcomes. However, several critical …

Background PD-1 inhibitors have been routinely used in the treatment of advanced non-
small cell lung cancer (NSCLC), and have demonstrated to significantly improve …

Background To evaluate the capability of basal and one-month differed white blood cells
(WBC), neutrophil, lymphocyte and platelet values and their ratios (neutrophils-to …